![Johnson & Johnson](https://pharmashots.com/public/default-image/default-730x400.png )
Johnson & Johnson to Acquire Numab's Yellow Jersey Therapeutics for an Aggregate of ~$1.25B
Shots:
- Johnson & Johnson has signed a definitive agreement with Numab Therapeutics, acquiring Yellow Jersey Therapeutics (Numab’s subsidiary) to gain worldwide rights of NM26 for an aggregate of ~$1.25B in cash
- NM26, a bispecific Ab, will be progressing to P-II study for treating atopic dermatitis. It targets IL-4Rα, that induces Th2-mediated skin inflammation, as well as IL-31, that affects skin itch & subsequent scratching leading to disease worsening; has the potential in other inflammatory skin diseases involving Th2 inflammation and itch
- Furthermore, the transaction is anticipated to conclude in the H2’24
Ref: Johnson & Johnson| Image: Johnson & Johnson
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
![](https://pharmashots.com/public/images/Disha-2023-03-21-64199f99761c8.png)
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.